The study will be conducted in 3 parts. Part 1 will evaluate vaccine efficacy (VE) and will last a minimum of 15 months. Part 2 will be for an additional 6 months to evaluate VE. Part 3 will evaluate long-term safety by following participants for side effects and will last an additional 3 years. Participants may be enrolled into a dry-run to commence and test febrile surveillance methodology; this dry-run part may be upto 10 months prior to receiving study injection, however, will not be applicable to all trials sites or participants.